Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-201 in moderate to severe plaque psoriasis
NCT01837420Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Nov 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of VB-201 in plaque psoriasis (3 arms), sponsored by VBL Therapeutics. Primary endpoint: Proportion of subjects achieving at least 50% improvement in PASI score at 24 weeks. Started Nov 2012; status: completed.
02
Drugs
VB-201
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01837420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01837420.